Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.54 |
| ▸ | RXRG | P48443 | 8/20 | 0.54 |
| ▸ | RXRB | P28702 | 7/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504122 | 0.87 | RXRA (0.68) | RXRARXRGRXRBPSEN1PSEN2 | |
| SCHEMBL22775743 | 0.86 | SLC13A3 (0.42) | RXRARXRGRXRBSLC13A3TACR1 | |
| SCHEMBL28500739 | 0.84 | CES1 (0.46) | RXRARXRGRXRBSLC13A3TACR1 | |
| SCHEMBL30151149 | 0.83 | THRA (0.50) | RXRARXRGRXRBTHRBSLC13A3 | |
| SCHEMBL21273844 | 0.80 | CA2 (0.50) | THRBMEN1GAAKMT2ATDP1 | |
| SCHEMBL868125 | 0.80 | CA2 (0.50) | THRBMEN1GAAKMT2ATDP1 | |
| SCHEMBL4494395 | 0.80 | RXRA (0.56) | RXRARXRGRXRBPSEN1PSEN2 | |
| SCHEMBL153296 | 0.80 | RXRA (0.67) | RXRARXRGRXRBPSEN1PSEN2 | |
| SCHEMBL17147284 | 0.79 | RXRA (0.54) | RXRARXRGRXRBPSEN1PSEN2 | |
| SCHEMBL22773948 | 0.79 | RXRA (0.54) | RXRARXRGRXRBPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-08-25 | — | — | US | disclosed |
| WO-2020249669-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| EP-2414346-B1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2010112124-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
| US-4054665-A | 2-Amino-5-(trifluoromethylphenylalkyl)-1,3,4 thiadiazoles used in the treatment of insomnia and anxiety | SANDOZ, INC. (US) | 1977-10-18 | — | — | US | disclosed |
| US-3965110-A | 2-Amino-5-(trifluoromethyl phenylalkyl)-1,3,4-thiadiazoles | SANDOZ, INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | RXRA 2995/4885RXRG 2968/4885RXRB 2878/4885 |
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | IL1B, IL1A, CASP1 | RXRA 2545/4885RXRG 2943/4885RXRB 2384/4885 |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | RXRA 2995/4885RXRG 2968/4885RXRB 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.